Plasma B-Type Natriuretic Peptide Levels May Increase Because of Fat Mass Loss by Metformin or Sodium-Glucose Transporter 2 Inhibitors Treatment

Abstract

Background: Cardiovascular disease (CVD) is the leading cause of death in type 2 diabetes. Metformin reduces cardiovascular events in obese patients with type 2 diabetes, and sodium-glucose transporter 2 (SGLT2) inhibitors decrease cardiovascular events in type 2 diabetic patients with established CVD. However, the underlying mechanisms behind the cardioprotective effects of metformin and SGLT2 inhibitors are unknown.

The potential protective effect of metformin on selective cardiac biomarkers in diabetic male rats

“…four months treatment with metformin reduced the BNP level in patientswith heart failure compared with non-treated patients (14). Also, its reported that treatment with metformin for 3 months lead to decrease the BNP level significantly when compared with nontreated rats (15). Matrix metalloproteinase is a protease involved in the tissue remodelling in both pathological and physiological conditions.…”